Clinical Pharmacokinetics of Fexofenadine: A Systematic Review

Background/Objectives: Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing research on the clinical pharmacokinetics (PK) of fexofenadine, with a copious emphasis on examining the impact of stereoisom...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 16; no. 12; p. 1619
Main Authors Batool, Maryam, Zamir, Ammara, Alqahtani, Faleh, Ahmad, Tanveer, Saeed, Hamid, Rasool, Muhammad Fawad
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.12.2024
Subjects
Chronic kidney failure
clearance
Collaboration
Content analysis
Drug dosages
Drugs
fexofenadine
Glycoproteins
Histamine
humans
Internet/Web search services
Medical research
Medicine, Experimental
Metronidazole
Permeability
Pharmacokinetics
Plasma
Prescribing
Search engines
Search strategies
second generation
Stereoisomers
Systematic review
Urticaria
United States > US
second generation
fexofenadine
pharmacokinetics
clearance
allergic rhinitis
systematic review
humans
AUC
Online AccessGet full text
ISSN1999-4923
1999-4923
DOI10.3390/pharmaceutics16121619

Cover

Abstract Background/Objectives: Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing research on the clinical pharmacokinetics (PK) of fexofenadine, with a copious emphasis on examining the impact of stereoisomerism, disease states, and drug interactions. Methods: The search engines PubMed, Science Direct, Google Scholar, and Cochrane were scanned systematically for articles concerning the clinical PK of fexofenadine in humans. The extensive literature search yielded 85 articles meeting the inclusion standards. Results: The PK parameters of fexofenadine showed a linear correlation between increasing doses and proportional elevations in PK parameters such as area under the curve from time 0 to infinity (AUC0–∞) and maximum plasma concentration (Cmax). Under fed conditions, its bioavailability was reduced by approximately 50%. Findings from patients with end-stage renal disease (ESRD) displayed a 63% decline in oral clearance (CL/F) of fexofenadine. A drug–food interaction study has displayed that grapefruit juice decreased Cmax (201 ng/mL vs. 128 ng/mL), accompanied by a 30% reduction in the bioavailability of fexofenadine. Furthermore, a drug–herb interaction study with St John’s Wort (SJW) has reported a reduction in CL/F by 10% after a single dose, but long-term administration reversed this effect, resulting in elevated CL/F by 17% of fexofenadine. Conclusions: Since no prior systematic review on the PK of this drug exists, this review amalgamates all pertinent PK parameters in humans by pooling up-to-date data from published studies. This detailed literature review can be advantageous for researchers who want to develop and assess PK models.
AbstractList Background/Objectives: Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing research on the clinical pharmacokinetics (PK) of fexofenadine, with a copious emphasis on examining the impact of stereoisomerism, disease states, and drug interactions. Methods: The search engines PubMed, Science Direct, Google Scholar, and Cochrane were scanned systematically for articles concerning the clinical PK of fexofenadine in humans. The extensive literature search yielded 85 articles meeting the inclusion standards. Results: The PK parameters of fexofenadine showed a linear correlation between increasing doses and proportional elevations in PK parameters such as area under the curve from time 0 to infinity (AUC0–∞) and maximum plasma concentration (Cmax). Under fed conditions, its bioavailability was reduced by approximately 50%. Findings from patients with end-stage renal disease (ESRD) displayed a 63% decline in oral clearance (CL/F) of fexofenadine. A drug–food interaction study has displayed that grapefruit juice decreased Cmax (201 ng/mL vs. 128 ng/mL), accompanied by a 30% reduction in the bioavailability of fexofenadine. Furthermore, a drug–herb interaction study with St John’s Wort (SJW) has reported a reduction in CL/F by 10% after a single dose, but long-term administration reversed this effect, resulting in elevated CL/F by 17% of fexofenadine. Conclusions: Since no prior systematic review on the PK of this drug exists, this review amalgamates all pertinent PK parameters in humans by pooling up-to-date data from published studies. This detailed literature review can be advantageous for researchers who want to develop and assess PK models.
Background/Objectives: Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing research on the clinical pharmacokinetics (PK) of fexofenadine, with a copious emphasis on examining the impact of stereoisomerism, disease states, and drug interactions. Methods: The search engines PubMed, Science Direct, Google Scholar, and Cochrane were scanned systematically for articles concerning the clinical PK of fexofenadine in humans. The extensive literature search yielded 85 articles meeting the inclusion standards. Results: The PK parameters of fexofenadine showed a linear correlation between increasing doses and proportional elevations in PK parameters such as area under the curve from time 0 to infinity (AUC[sub.0–∞]) and maximum plasma concentration (C[sub.max]). Under fed conditions, its bioavailability was reduced by approximately 50%. Findings from patients with end-stage renal disease (ESRD) displayed a 63% decline in oral clearance (CL/F) of fexofenadine. A drug–food interaction study has displayed that grapefruit juice decreased C[sub.max] (201 ng/mL vs. 128 ng/mL), accompanied by a 30% reduction in the bioavailability of fexofenadine. Furthermore, a drug–herb interaction study with St John’s Wort (SJW) has reported a reduction in CL/F by 10% after a single dose, but long-term administration reversed this effect, resulting in elevated CL/F by 17% of fexofenadine. Conclusions: Since no prior systematic review on the PK of this drug exists, this review amalgamates all pertinent PK parameters in humans by pooling up-to-date data from published studies. This detailed literature review can be advantageous for researchers who want to develop and assess PK models.
Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing research on the clinical pharmacokinetics (PK) of fexofenadine, with a copious emphasis on examining the impact of stereoisomerism, disease states, and drug interactions. The search engines PubMed, Science Direct, Google Scholar, and Cochrane were scanned systematically for articles concerning the clinical PK of fexofenadine in humans. The extensive literature search yielded 85 articles meeting the inclusion standards. The PK parameters of fexofenadine showed a linear correlation between increasing doses and proportional elevations in PK parameters such as area under the curve from time 0 to infinity (AUC ) and maximum plasma concentration (C ). Under fed conditions, its bioavailability was reduced by approximately 50%. Findings from patients with end-stage renal disease (ESRD) displayed a 63% decline in oral clearance (CL/F) of fexofenadine. A drug-food interaction study has displayed that grapefruit juice decreased C (201 ng/mL vs. 128 ng/mL), accompanied by a 30% reduction in the bioavailability of fexofenadine. Furthermore, a drug-herb interaction study with St John's Wort (SJW) has reported a reduction in CL/F by 10% after a single dose, but long-term administration reversed this effect, resulting in elevated CL/F by 17% of fexofenadine. Since no prior systematic review on the PK of this drug exists, this review amalgamates all pertinent PK parameters in humans by pooling up-to-date data from published studies. This detailed literature review can be advantageous for researchers who want to develop and assess PK models.
Background/Objectives: Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing research on the clinical pharmacokinetics (PK) of fexofenadine, with a copious emphasis on examining the impact of stereoisomerism, disease states, and drug interactions. Methods: The search engines PubMed, Science Direct, Google Scholar, and Cochrane were scanned systematically for articles concerning the clinical PK of fexofenadine in humans. The extensive literature search yielded 85 articles meeting the inclusion standards. Results: The PK parameters of fexofenadine showed a linear correlation between increasing doses and proportional elevations in PK parameters such as area under the curve from time 0 to infinity (AUC0-∞) and maximum plasma concentration (Cmax). Under fed conditions, its bioavailability was reduced by approximately 50%. Findings from patients with end-stage renal disease (ESRD) displayed a 63% decline in oral clearance (CL/F) of fexofenadine. A drug-food interaction study has displayed that grapefruit juice decreased Cmax (201 ng/mL vs. 128 ng/mL), accompanied by a 30% reduction in the bioavailability of fexofenadine. Furthermore, a drug-herb interaction study with St John's Wort (SJW) has reported a reduction in CL/F by 10% after a single dose, but long-term administration reversed this effect, resulting in elevated CL/F by 17% of fexofenadine. Conclusions: Since no prior systematic review on the PK of this drug exists, this review amalgamates all pertinent PK parameters in humans by pooling up-to-date data from published studies. This detailed literature review can be advantageous for researchers who want to develop and assess PK models.Background/Objectives: Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing research on the clinical pharmacokinetics (PK) of fexofenadine, with a copious emphasis on examining the impact of stereoisomerism, disease states, and drug interactions. Methods: The search engines PubMed, Science Direct, Google Scholar, and Cochrane were scanned systematically for articles concerning the clinical PK of fexofenadine in humans. The extensive literature search yielded 85 articles meeting the inclusion standards. Results: The PK parameters of fexofenadine showed a linear correlation between increasing doses and proportional elevations in PK parameters such as area under the curve from time 0 to infinity (AUC0-∞) and maximum plasma concentration (Cmax). Under fed conditions, its bioavailability was reduced by approximately 50%. Findings from patients with end-stage renal disease (ESRD) displayed a 63% decline in oral clearance (CL/F) of fexofenadine. A drug-food interaction study has displayed that grapefruit juice decreased Cmax (201 ng/mL vs. 128 ng/mL), accompanied by a 30% reduction in the bioavailability of fexofenadine. Furthermore, a drug-herb interaction study with St John's Wort (SJW) has reported a reduction in CL/F by 10% after a single dose, but long-term administration reversed this effect, resulting in elevated CL/F by 17% of fexofenadine. Conclusions: Since no prior systematic review on the PK of this drug exists, this review amalgamates all pertinent PK parameters in humans by pooling up-to-date data from published studies. This detailed literature review can be advantageous for researchers who want to develop and assess PK models.
Audience Academic
Author Zamir, Ammara
Alqahtani, Faleh
Ahmad, Tanveer
Saeed, Hamid
Batool, Maryam
Rasool, Muhammad Fawad
Author_xml – sequence: 1
  givenname: Maryam
  surname: Batool
  fullname: Batool, Maryam
– sequence: 2
  givenname: Ammara
  surname: Zamir
  fullname: Zamir, Ammara
– sequence: 3
  givenname: Faleh
  orcidid: 0000-0003-3924-593X
  surname: Alqahtani
  fullname: Alqahtani, Faleh
– sequence: 4
  givenname: Tanveer
  orcidid: 0000-0001-8805-0296
  surname: Ahmad
  fullname: Ahmad, Tanveer
– sequence: 5
  givenname: Hamid
  orcidid: 0000-0002-1400-4825
  surname: Saeed
  fullname: Saeed, Hamid
– sequence: 6
  givenname: Muhammad Fawad
  orcidid: 0000-0002-8607-8583
  surname: Rasool
  fullname: Rasool, Muhammad Fawad
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39771597$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1vFCEUhompsR_2J2gm8cabrcPCMHO8MNlsrDZpotHekzMHqKwzwwoz1v33ZZ1aP9ILIQRyeM7L4YVjdjCEwTL2jJdnQkD5avsFY49kp9FT4oov84BH7IgDwELCUhz8sT5kpyltytyE4I2AJ-xQQF3zCuoj9mbd-cETdsXHWTN89YPdyxbBFef2R3B2QJNjr4tV8XmXRttj3i4-2e_e3jxljx12yZ7ezSfs6vzt1fr94vLDu4v16nJBUlXjghOhIWXAcUUcsUFCrqAxVLpKmrwrBalGuNq0rWlE4xR3FRBgaUtcihN2McuagBu9jb7HuNMBvf4ZCPFaY8xVdVYrFIQNOVkjyYpqaKsWHFBrHFhl91pq1pqGLe5usOvuBXmp9_bqB-3NiS_nxG0M3yabRt37RLbrcLBhSlrwSjTZViky-uIfdBOmOGSHMiWhlgCS_6auMRfuBxfGiLQX1atmyYHXZVln6uwBKndje0_5Xzif438lPL87fGp7a-5v9-vRM1DNAMWQUrTuPw24BYqpxLk
Cites_doi 10.1067/mcp.2002.124080
10.1038/sj.clpt.6100104
10.1067/mcp.2001.113697
10.3109/00498254.2010.515318
10.1002/bmc.3650
10.1016/S1871-5125(09)34004-2
10.1002/jcph.136
10.1016/j.clpt.2004.08.026
10.1097/FPC.0b013e32834300cc
10.1046/j.1365-2125.2002.01591.x
10.1177/0091270008319707
10.1080/00498254.2016.1180564
10.1111/bcp.13080
10.1097/FTD.0b013e3181bf7db6
10.1007/s00228-016-2173-3
10.1016/j.jchromb.2020.122094
10.2500/aap.2008.29.3136
10.1124/dmd.106.011023
10.1016/S0091-6749(03)01880-3
10.1016/j.clpt.2004.08.002
10.5507/bp.2007.011
10.1016/S0009-9236(03)00238-8
10.1016/j.clpt.2004.10.005
10.1016/j.clpt.2005.04.012
10.1007/s11095-020-02854-4
10.1124/dmd.113.053991
10.1111/j.1365-2125.2011.04106.x
10.1007/s00228-009-0627-6
10.1111/j.1472-8206.2004.00254.x
10.1177/0091270006288733
10.1111/cts.12400
10.1111/j.1365-2125.2008.03116.x
10.1016/S0091-6749(96)80192-8
10.1159/000321896
10.1136/bmj.d5928
10.1007/s00228-010-0797-2
10.1002/bmc.1296
10.1124/dmd.112.048330
10.1038/clpt.2008.102
10.1016/j.jep.2013.01.037
10.2165/00003495-200059020-00020
10.3109/10837450.2014.882942
10.1016/S0140-6736(05)65003-9
10.1111/j.1365-2125.2006.02689.x
10.1517/17425250903044967
10.1016/S0149-2918(01)80049-7
10.1016/j.ejps.2010.03.009
10.1016/S0197-2456(99)00026-4
10.1177/0091270004273320
10.1007/s00228-016-2050-0
10.1016/S0009-9236(98)90052-2
10.1186/s13223-021-00614-6
10.1097/JCP.0b013e318248ddb9
10.1016/j.clpt.2005.11.001
10.1016/j.jep.2019.112174
10.3233/WOR-2012-1039-4218
10.1067/mcp.2002.121152
10.1016/j.drugalcdep.2008.12.009
10.1002/phar.1347
10.1185/030079905X59175
10.1097/ALN.0b013e3181986a9a
10.1016/j.ijsu.2010.02.007
10.3390/jpm9040045
10.1007/s11096-022-01390-y
10.1016/j.dmpk.2015.06.005
10.15586/aei.v49i4.89
10.1166/sl.2020.4190
10.1002/(SICI)1099-081X(199810)19:7<455::AID-BDD130>3.0.CO;2-W
10.1002/cpt.1875
10.1002/jcph.62
10.1097/ALN.0b013e3182423478
10.1002/cpt.2682
10.1053/j.ajkd.2014.09.015
10.1067/mcp.2003.10
10.1002/chir.20370
10.1002/cpdd.1311
10.1111/jcpt.12213
10.1089/pai.1999.13.163
10.1016/j.waojou.2022.100658
10.1080/00498254.2020.1857467
10.1002/jcph.1403
10.2165/00003088-200847040-00001
10.1681/ASN.2009010082
10.1016/j.jpba.2018.10.029
10.1155/2014/473213
10.2165/00003088-200241040-00004
10.1007/s00228-014-1705-y
10.1016/S0378-4347(01)00468-6
10.1186/s40360-019-0363-1
10.1111/j.1365-2125.2006.02613.x
10.1592/phco.30.8.797
10.1136/bmjopen-2021-057151
10.1016/j.dmpk.2015.01.002
10.1111/j.1365-2710.2009.01159.x
10.1111/j.1365-2125.2009.03396.x
10.1046/j.1365-2125.2003.01902.x
10.1002/9780470712184
10.4155/tde-2020-0042
10.2165/00003088-199936050-00003
10.1177/0018578718776857
10.1365/s10337-008-0526-5
10.2165/11597070-000000000-00000
10.1002/bmc.3114
10.1016/S1005-9040(07)60112-3
10.1185/030079908X260871
10.1177/0091270011407194
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
NPM
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
ADTOC
UNPAY
DOA
DOI 10.3390/pharmaceutics16121619
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

PubMed
CrossRef
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1999-4923
ExternalDocumentID oai_doaj_org_article_6a3ca8cf47ac45c79b5b9f9cbdf9e6e2
10.3390/pharmaceutics16121619
A821917007
39771597
10_3390_pharmaceutics16121619
Genre Journal Article
Review
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: King Saud University
  grantid: RSP2024R131
GroupedDBID ---
53G
5VS
8G5
AADQD
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACUHS
AEAQA
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BPHCQ
CCPQU
CITATION
DIK
DWQXO
EBD
ESX
F5P
FD6
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HH5
HYE
IAO
IHR
ITC
KQ8
M2O
M48
MK0
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PUEGO
RNS
RPM
TR2
TUS
NPM
PMFND
3V.
7XB
8FK
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
ADRAZ
ADTOC
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c465t-1ccadc6d9f16c1aa8aca1698dc0f54dcca43c683f7dbbd838f61f59c9a0e0a23
IEDL.DBID M48
ISSN 1999-4923
IngestDate Wed Aug 27 01:23:51 EDT 2025
Tue Aug 19 23:59:27 EDT 2025
Thu Sep 04 17:18:20 EDT 2025
Mon Jun 30 13:27:17 EDT 2025
Tue Jun 17 22:01:31 EDT 2025
Tue Jun 10 21:09:41 EDT 2025
Mon Jul 21 05:46:55 EDT 2025
Wed Oct 01 01:02:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords second generation
fexofenadine
pharmacokinetics
clearance
allergic rhinitis
systematic review
humans
AUC
Language English
License https://creativecommons.org/licenses/by/4.0
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-1ccadc6d9f16c1aa8aca1698dc0f54dcca43c683f7dbbd838f61f59c9a0e0a23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-3924-593X
0000-0002-8607-8583
0000-0002-1400-4825
0000-0001-8805-0296
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.mdpi.com/1999-4923/16/12/1619/pdf?version=1734701031
PMID 39771597
PQID 3149749941
PQPubID 2032349
ParticipantIDs doaj_primary_oai_doaj_org_article_6a3ca8cf47ac45c79b5b9f9cbdf9e6e2
unpaywall_primary_10_3390_pharmaceutics16121619
proquest_miscellaneous_3153871543
proquest_journals_3149749941
gale_infotracmisc_A821917007
gale_infotracacademiconefile_A821917007
pubmed_primary_39771597
crossref_primary_10_3390_pharmaceutics16121619
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-12-01
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-12-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Pharmaceutics
PublicationTitleAlternate Pharmaceutics
PublicationYear 2024
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Gupta (ref_66) 2001; 23
Mendoza (ref_45) 2007; 151
Joy (ref_55) 2014; 34
Nolin (ref_50) 2009; 20
ref_11
Wang (ref_68) 2002; 71
ref_10
Drescher (ref_41) 2002; 53
Kusuhara (ref_19) 2013; 41
Akamine (ref_101) 2014; 70
Moher (ref_33) 2010; 8
Dresser (ref_75) 2005; 77
Mancano (ref_27) 2018; 53
Carnovale (ref_31) 2022; 15
Kharasch (ref_85) 2009; 101
Tomaru (ref_103) 2015; 30
Clark (ref_34) 1999; 20
Barnett (ref_6) 1996; 348
Yamada (ref_7) 2009; 31
Bedada (ref_110) 2017; 73
Shimizu (ref_78) 2006; 61
Uno (ref_79) 2006; 34
Devillier (ref_8) 2008; 47
ref_23
Kim (ref_107) 2016; 82
Chretien (ref_65) 2023; 13
Saruwatari (ref_93) 2012; 32
Won (ref_97) 2013; 53
Handley (ref_3) 1999; 13
ref_26
Segall (ref_49) 2008; 29
Misaka (ref_114) 2022; 112
Russell (ref_39) 1998; 64
Bedada (ref_109) 2017; 47
Imanaga (ref_91) 2011; 21
Thewlis (ref_35) 2012; 41
Bharathi (ref_48) 2008; 67
Lemma (ref_77) 2006; 79
Fischer (ref_4) 2010; 32
Helmy (ref_12) 2020; 11
Muppavarapu (ref_53) 2014; 28
Malati (ref_92) 2012; 52
Cusinato (ref_111) 2019; 245
Asha (ref_5) 2020; 18
Calvo (ref_59) 2019; 59
Hofmann (ref_42) 2002; 766
Simons (ref_14) 1999; 36
Everardo (ref_63) 2021; 49
Simpson (ref_29) 2000; 59
Hamman (ref_67) 2001; 69
Pinto (ref_24) 2020; 37
Robbins (ref_40) 1998; 19
Akamine (ref_104) 2015; 40
Tannergren (ref_22) 2003; 74
Bedada (ref_100) 2014; 6
Zhou (ref_98) 2013; 146
Teng (ref_47) 2007; 23
Rauch (ref_64) 2023; 12
Zhao (ref_113) 2021; 51
Kim (ref_86) 2009; 65
Meltzer (ref_28) 2021; 17
Gubler (ref_106) 2016; 72
Akamine (ref_16) 2012; 73
Chen (ref_54) 2014; 27
Higgins (ref_37) 2011; 343
Miura (ref_46) 2007; 19
Yi (ref_43) 2004; 76
Banfield (ref_69) 2002; 41
Kharasch (ref_94) 2012; 116
Kharasch (ref_87) 2009; 110
Dicpinigaitis (ref_1) 2003; 56
Yasuifurukori (ref_74) 2005; 77
Simons (ref_38) 1996; 98
Qiu (ref_102) 2014; 2014
Soliman (ref_36) 2022; 44
Thomson (ref_57) 2015; 65
Dresser (ref_70) 2002; 71
Penzak (ref_90) 2010; 30
Shimizu (ref_80) 2006; 62
Sakugawa (ref_88) 2009; 67
Lappin (ref_21) 2010; 40
Akamine (ref_51) 2010; 40
Smith (ref_30) 2009; 5
Kim (ref_89) 2010; 66
Tateishi (ref_84) 2008; 65
Valizadeh (ref_20) 2009; 59
Shon (ref_72) 2005; 78
Ciprandi (ref_2) 2003; 112
Yamazaki (ref_13) 2010; 35
Ieiri (ref_99) 2013; 53
ref_32
Pinto (ref_61) 2020; 1145
ref_112
Dresser (ref_71) 2003; 73
Yehia (ref_56) 2015; 20
Bailey (ref_81) 2007; 81
Croft (ref_95) 2012; 51
Luo (ref_108) 2016; 9
Helmy (ref_58) 2016; 30
Axelrod (ref_9) 2008; 1
Akamine (ref_105) 2015; 30
Compalati (ref_25) 2011; 156
Molimard (ref_15) 2004; 18
Liu (ref_18) 2008; 48
Rolf (ref_76) 2006; 46
Kharasch (ref_96) 2013; 41
Egeland (ref_62) 2020; 108
Abilash (ref_17) 2022; 11
Robertson (ref_82) 2008; 24
Guo (ref_52) 2010; 24
Cusinato (ref_60) 2019; 164
Xie (ref_73) 2005; 45
Boyle (ref_44) 2005; 21
Kharasch (ref_83) 2008; 84
References_xml – volume: 71
  start-page: 414
  year: 2002
  ident: ref_68
  article-title: Effect of St John’s wort on the pharmacokinetics of fexofenadine
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1067/mcp.2002.124080
– volume: 81
  start-page: 495
  year: 2007
  ident: ref_81
  article-title: Naringin is a major and selective clinical inhibitor of organic anion-transporting poly-peptide 1A2 (OATP1A2) in grapefruit juice
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/sj.clpt.6100104
– volume: 69
  start-page: 114
  year: 2001
  ident: ref_67
  article-title: The effect of rifampin administration on the disposition of fexofenadine
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1067/mcp.2001.113697
– volume: 40
  start-page: 782
  year: 2010
  ident: ref_51
  article-title: Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2010.515318
– volume: 30
  start-page: 1059
  year: 2016
  ident: ref_58
  article-title: HPLC Determination of Fexofenadine in Human Plasma for Therapeutic Drug Monitoring and Pharmacokinetic Studies
  publication-title: Biomed. Chromatogr.
  doi: 10.1002/bmc.3650
– ident: ref_23
  doi: 10.1016/S1871-5125(09)34004-2
– volume: 53
  start-page: 982
  year: 2013
  ident: ref_97
  article-title: A Modified Grapefruit Juice Eliminates Two Compound Classes as Major Mediators of the Grapefruit Juice–Fexofenadine Interaction: An In Vitro–In Vivo “Connect”
  publication-title: J. Clin. Pharmacol.
  doi: 10.1002/jcph.136
– volume: 77
  start-page: 17
  year: 2005
  ident: ref_74
  article-title: Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1016/j.clpt.2004.08.026
– volume: 21
  start-page: 84
  year: 2011
  ident: ref_91
  article-title: The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharma-cokinetics of fexofenadine and midazolam in humans
  publication-title: Pharmacogenet Genom.
  doi: 10.1097/FPC.0b013e32834300cc
– volume: 53
  start-page: 526
  year: 2002
  ident: ref_41
  article-title: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofena-dine
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1046/j.1365-2125.2002.01591.x
– volume: 48
  start-page: 957
  year: 2008
  ident: ref_18
  article-title: Probenecid, but Not Cystic Fibrosis, Alters the Total and Renal Clearance of Fexofenadine
  publication-title: J. Clin. Pharmacol.
  doi: 10.1177/0091270008319707
– volume: 47
  start-page: 230
  year: 2017
  ident: ref_109
  article-title: The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human vol-unteers
  publication-title: Xenobiotica
  doi: 10.1080/00498254.2016.1180564
– volume: 82
  start-page: 1580
  year: 2016
  ident: ref_107
  article-title: Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/bcp.13080
– volume: 31
  start-page: 764
  year: 2009
  ident: ref_7
  article-title: Effects of the P-glycoprotein inducer carbamazepine on fexofenadine phar-macokinetics
  publication-title: Ther. Drug Monit.
  doi: 10.1097/FTD.0b013e3181bf7db6
– volume: 73
  start-page: 343
  year: 2017
  ident: ref_110
  article-title: The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-016-2173-3
– volume: 27
  start-page: 1261
  year: 2014
  ident: ref_54
  article-title: Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers
  publication-title: Pak. J. Pharm. Sci.
– volume: 1145
  start-page: 122094
  year: 2020
  ident: ref_61
  article-title: Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study
  publication-title: J. Chromatogr. B
  doi: 10.1016/j.jchromb.2020.122094
– volume: 29
  start-page: 380
  year: 2008
  ident: ref_49
  article-title: Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis
  publication-title: Allergy Asthma Proc.
  doi: 10.2500/aap.2008.29.3136
– volume: 34
  start-page: 1875
  year: 2006
  ident: ref_79
  article-title: Lack of Dose-Dependent Effects of Itraconazole on the Pharmacokinetic Interaction with Fexofenadine
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.106.011023
– volume: 112
  start-page: S78
  year: 2003
  ident: ref_2
  article-title: Effects of fexofenadine and other antihistamines on components of the allergic response: Adhesion molecules
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/S0091-6749(03)01880-3
– volume: 32
  start-page: 12
  year: 2010
  ident: ref_4
  article-title: Analogue-based drug discovery
  publication-title: Chem. Int. Newsmag. IUPAC
– volume: 76
  start-page: 418
  year: 2004
  ident: ref_43
  article-title: A variant 2677A allele of the MDR1 gene affects fexofenadine disposition
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2004.08.002
– volume: 151
  start-page: 65
  year: 2007
  ident: ref_45
  article-title: Bioequivalence of two fexofenadine formulations in healthy human volunteers after single oral administration
  publication-title: Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc
  doi: 10.5507/bp.2007.011
– ident: ref_10
– volume: 74
  start-page: 423
  year: 2003
  ident: ref_22
  article-title: Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1016/S0009-9236(03)00238-8
– volume: 77
  start-page: 170
  year: 2005
  ident: ref_75
  article-title: Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides*
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1016/j.clpt.2004.10.005
– volume: 78
  start-page: 191
  year: 2005
  ident: ref_72
  article-title: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1016/j.clpt.2005.04.012
– volume: 37
  start-page: 131
  year: 2020
  ident: ref_24
  article-title: Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-020-02854-4
– volume: 41
  start-page: 2166
  year: 2013
  ident: ref_96
  article-title: Cytochrome P4503A Does Not Mediate the Interaction between Methadone and Ritonavir-Lopinavir
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.113.053991
– volume: 73
  start-page: 478
  year: 2012
  ident: ref_16
  article-title: Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2011.04106.x
– volume: 65
  start-page: 609
  year: 2009
  ident: ref_86
  article-title: Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-009-0627-6
– volume: 18
  start-page: 399
  year: 2004
  ident: ref_15
  article-title: Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans
  publication-title: Fundam. Clin. Pharmacol.
  doi: 10.1111/j.1472-8206.2004.00254.x
– volume: 46
  start-page: 758
  year: 2006
  ident: ref_76
  article-title: Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine
  publication-title: J. Clin. Pharmacol.
  doi: 10.1177/0091270006288733
– volume: 9
  start-page: 201
  year: 2016
  ident: ref_108
  article-title: The Pharmacokinetic Exposure to Fexofenadine is Volume-Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice
  publication-title: Clin. Transl. Sci.
  doi: 10.1111/cts.12400
– volume: 65
  start-page: 693
  year: 2008
  ident: ref_84
  article-title: The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2008.03116.x
– volume: 98
  start-page: 1062
  year: 1996
  ident: ref_38
  article-title: The clinical pharmacology of fexofenadine in children
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/S0091-6749(96)80192-8
– volume: 156
  start-page: 1
  year: 2011
  ident: ref_25
  article-title: Systematic Review on the Efficacy of Fexofenadine in Seasonal Allergic Rhinitis: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Clinical Trials
  publication-title: Int. Arch. Allergy Immunol.
  doi: 10.1159/000321896
– volume: 343
  start-page: d5928
  year: 2011
  ident: ref_37
  article-title: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
  publication-title: BMJ
  doi: 10.1136/bmj.d5928
– volume: 66
  start-page: 721
  year: 2010
  ident: ref_89
  article-title: Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-010-0797-2
– volume: 24
  start-page: 335
  year: 2010
  ident: ref_52
  article-title: Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: Application to a clinical pharmacokinetic study
  publication-title: Biomed. Chromatogr.
  doi: 10.1002/bmc.1296
– ident: ref_11
– volume: 41
  start-page: 206
  year: 2013
  ident: ref_19
  article-title: Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.112.048330
– volume: 84
  start-page: 506
  year: 2008
  ident: ref_83
  article-title: Mechanism of ritonavir changes in methadone pharmacokinetics and pharmaco-dynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2008.102
– volume: 146
  start-page: 744
  year: 2013
  ident: ref_98
  article-title: Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe
  publication-title: J. Ethnopharmacol.
  doi: 10.1016/j.jep.2013.01.037
– volume: 59
  start-page: 301
  year: 2000
  ident: ref_29
  article-title: Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
  publication-title: Drugs
  doi: 10.2165/00003495-200059020-00020
– volume: 1
  start-page: 19
  year: 2008
  ident: ref_9
  article-title: Fexofenadine hydrochloride in the treatment of allergic disease: A review
  publication-title: J. Asthma Allergy
– volume: 20
  start-page: 528
  year: 2015
  ident: ref_56
  article-title: Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: Development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers
  publication-title: Pharm. Dev. Technol.
  doi: 10.3109/10837450.2014.882942
– volume: 348
  start-page: 395
  year: 1996
  ident: ref_6
  article-title: FDA approves safer form of terfenadine
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)65003-9
– volume: 62
  start-page: 372
  year: 2006
  ident: ref_80
  article-title: Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofen-adine, a substrate of P-glycoprotein
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2006.02689.x
– volume: 5
  start-page: 813
  year: 2009
  ident: ref_30
  article-title: Fexofenadine: Biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders
  publication-title: Expert. Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425250903044967
– volume: 23
  start-page: 451
  year: 2001
  ident: ref_66
  article-title: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coad-ministered with azithromycin: A randomized, placebo-controlled, parallel-group study
  publication-title: Clin. Ther.
  doi: 10.1016/S0149-2918(01)80049-7
– volume: 40
  start-page: 125
  year: 2010
  ident: ref_21
  article-title: Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2010.03.009
– volume: 20
  start-page: 448
  year: 1999
  ident: ref_34
  article-title: Assessing the quality of randomized trials: Reliability of the Jadad scale
  publication-title: Control. Clin. Trials
  doi: 10.1016/S0197-2456(99)00026-4
– volume: 45
  start-page: 352
  year: 2005
  ident: ref_73
  article-title: CYP3A and P-glycoprotein activity induction with St. John’s Wort in healthy volunteers from 6 ethnic populations
  publication-title: J. Clin. Pharmacol.
  doi: 10.1177/0091270004273320
– volume: 72
  start-page: 797
  year: 2016
  ident: ref_106
  article-title: No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-016-2050-0
– volume: 64
  start-page: 612
  year: 1998
  ident: ref_39
  article-title: Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1016/S0009-9236(98)90052-2
– volume: 17
  start-page: 113
  year: 2021
  ident: ref_28
  article-title: Fexofenadine: Review of safety, efficacy and unmet needs in children with allergic rhinitis
  publication-title: Allergy, Asthma Clin. Immunol.
  doi: 10.1186/s13223-021-00614-6
– volume: 32
  start-page: 195
  year: 2012
  ident: ref_93
  article-title: Different Effects of the Selective Serotonin Reuptake Inhibitors Fluvoxamine, Paroxetine, and Sertraline on the Pharmacokinetics of Fexofenadine in Healthy Volunteers
  publication-title: J. Clin. Psychopharmacol.
  doi: 10.1097/JCP.0b013e318248ddb9
– volume: 79
  start-page: 218
  year: 2006
  ident: ref_77
  article-title: The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1016/j.clpt.2005.11.001
– volume: 245
  start-page: 112174
  year: 2019
  ident: ref_111
  article-title: Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach
  publication-title: J. Ethnopharmacol.
  doi: 10.1016/j.jep.2019.112174
– volume: 41
  start-page: 4218
  year: 2012
  ident: ref_35
  article-title: A Comprehensive Literature Review of the Pelvis and the Lower Extremity FE Human Models under Quasi-static Conditions
  publication-title: Work.
  doi: 10.3233/WOR-2012-1039-4218
– volume: 71
  start-page: 11
  year: 2002
  ident: ref_70
  article-title: Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1067/mcp.2002.121152
– volume: 101
  start-page: 158
  year: 2009
  ident: ref_85
  article-title: Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity
  publication-title: Drug Alcohol. Depend.
  doi: 10.1016/j.drugalcdep.2008.12.009
– volume: 34
  start-page: 114
  year: 2014
  ident: ref_55
  article-title: In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases
  publication-title: Pharmacother. J. Hum. Pharmacol. Drug Ther.
  doi: 10.1002/phar.1347
– volume: 21
  start-page: 1495
  year: 2005
  ident: ref_44
  article-title: Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers
  publication-title: Curr. Med. Res. Opin.
  doi: 10.1185/030079905X59175
– volume: 110
  start-page: 660
  year: 2009
  ident: ref_87
  article-title: Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir/indinavir
  publication-title: Anesthesiology
  doi: 10.1097/ALN.0b013e3181986a9a
– volume: 8
  start-page: 336
  year: 2010
  ident: ref_33
  article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
  publication-title: Int. J. Surg.
  doi: 10.1016/j.ijsu.2010.02.007
– ident: ref_112
  doi: 10.3390/jpm9040045
– volume: 44
  start-page: 894
  year: 2022
  ident: ref_36
  article-title: The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies
  publication-title: Int. J. Clin. Pharm. Weekbl.
  doi: 10.1007/s11096-022-01390-y
– volume: 30
  start-page: 352
  year: 2015
  ident: ref_105
  article-title: The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion
  publication-title: Drug Metab. Pharmacokinet.
  doi: 10.1016/j.dmpk.2015.06.005
– volume: 49
  start-page: 15
  year: 2021
  ident: ref_63
  article-title: Bioavailability assessment of fexofenadine and montelukast in a fixed-dose combination tablet versus the components administered simultaneously
  publication-title: Allergol. Immunopathol.
  doi: 10.15586/aei.v49i4.89
– volume: 18
  start-page: 64
  year: 2020
  ident: ref_5
  article-title: Properties of Potassium Permanganate as Oxidant in the Determination of Fexofenadine in Pharmaceuticals
  publication-title: Sens. Lett.
  doi: 10.1166/sl.2020.4190
– volume: 19
  start-page: 455
  year: 1998
  ident: ref_40
  article-title: Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/(SICI)1099-081X(199810)19:7<455::AID-BDD130>3.0.CO;2-W
– volume: 108
  start-page: 866
  year: 2020
  ident: ref_62
  article-title: Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients with End-Stage Renal Disease
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1875
– volume: 53
  start-page: 654
  year: 2013
  ident: ref_99
  article-title: Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; mi-cro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs
  publication-title: J. Clin. Pharmacol.
  doi: 10.1002/jcph.62
– volume: 116
  start-page: 432
  year: 2012
  ident: ref_94
  article-title: Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A)
  publication-title: Anesthesiology
  doi: 10.1097/ALN.0b013e3182423478
– volume: 112
  start-page: 627
  year: 2022
  ident: ref_114
  article-title: Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.2682
– volume: 65
  start-page: 574
  year: 2015
  ident: ref_57
  article-title: Effect of CKD and Dialysis Modality on Exposure to Drugs Cleared by Nonrenal Mechanisms
  publication-title: Am. J. Kidney Dis.
  doi: 10.1053/j.ajkd.2014.09.015
– volume: 73
  start-page: 41
  year: 2003
  ident: ref_71
  article-title: Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1067/mcp.2003.10
– volume: 19
  start-page: 223
  year: 2007
  ident: ref_46
  article-title: Pharmacokinetics of fexofenadine enantiomers in healthy subjects
  publication-title: Chirality
  doi: 10.1002/chir.20370
– volume: 12
  start-page: 1194
  year: 2023
  ident: ref_64
  article-title: Bioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension
  publication-title: Clin. Pharmacol. Drug Dev.
  doi: 10.1002/cpdd.1311
– volume: 40
  start-page: 98
  year: 2015
  ident: ref_104
  article-title: Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexof-enadine enantiomers in Japanese volunteers
  publication-title: J. Clin. Pharm. Ther.
  doi: 10.1111/jcpt.12213
– volume: 13
  start-page: 163
  year: 1999
  ident: ref_3
  article-title: Advancement of the Third Generation of Antihistamines
  publication-title: Pediatr. Asthma Allergy Immunol.
  doi: 10.1089/pai.1999.13.163
– volume: 15
  start-page: 100658
  year: 2022
  ident: ref_31
  article-title: Safety of fexofenadine and other second-generation oral antihistamines before and after the removal of the prescription requirement in Italy and other European countries: A real-world evidence study and systematic review
  publication-title: World Allergy Organ. J.
  doi: 10.1016/j.waojou.2022.100658
– volume: 51
  start-page: 366
  year: 2021
  ident: ref_113
  article-title: Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers
  publication-title: Xenobiotica
  doi: 10.1080/00498254.2020.1857467
– volume: 59
  start-page: 1099
  year: 2019
  ident: ref_59
  article-title: Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients with Advanced EGFR-Mutated Non–Small Cell Lung Cancer
  publication-title: J. Clin. Pharmacol.
  doi: 10.1002/jcph.1403
– volume: 47
  start-page: 217
  year: 2008
  ident: ref_8
  article-title: Clinical Pharmacokinetics and Pharmacodynamics of Desloratadine, Fexofenadine and Levocetirizine: A comparative review
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/00003088-200847040-00001
– volume: 59
  start-page: 345
  year: 2009
  ident: ref_20
  article-title: Bioequivalence of Fexofenadine Tablet Formulations Assessed in Healthy Iranian Volunteers
  publication-title: Arzneimittelforschung
– volume: 20
  start-page: 2269
  year: 2009
  ident: ref_50
  article-title: ESRD Impairs Nonrenal Clearance of Fexofenadine but not Midazolam
  publication-title: J. Am. Soc. Nephrol.
  doi: 10.1681/ASN.2009010082
– volume: 164
  start-page: 430
  year: 2019
  ident: ref_60
  article-title: LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2018.10.029
– volume: 2014
  start-page: 473213
  year: 2014
  ident: ref_102
  article-title: Effects of Danshen Ethanol Extract on the Pharmacokinetics of Fexofenadine in Healthy Volunteers
  publication-title: Evidence-Based Complement. Altern. Med.
  doi: 10.1155/2014/473213
– volume: 41
  start-page: 311
  year: 2002
  ident: ref_69
  article-title: Grapefruit Juice Reduces the Oral Bioavailability of Fexofenadine But Not Desloratadine
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/00003088-200241040-00004
– volume: 70
  start-page: 1087
  year: 2014
  ident: ref_101
  article-title: Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine en-antiomers
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/s00228-014-1705-y
– volume: 766
  start-page: 227
  year: 2002
  ident: ref_42
  article-title: Determination of fexofenadine in human plasma and urine by liquid chromatog-raphy-mass spectrometry
  publication-title: J. Chromatogr. B Anal. Technol. Biomed. Life Sci.
  doi: 10.1016/S0378-4347(01)00468-6
– ident: ref_26
  doi: 10.1186/s40360-019-0363-1
– volume: 61
  start-page: 538
  year: 2006
  ident: ref_78
  article-title: Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2006.02613.x
– volume: 30
  start-page: 797
  year: 2010
  ident: ref_90
  article-title: Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.30.8.797
– volume: 13
  start-page: e057151
  year: 2023
  ident: ref_65
  article-title: Severity of coeliac disease and clinical management study when using a non-metabolised medication: A phase I pharmacokinetic study
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2021-057151
– volume: 30
  start-page: 221
  year: 2015
  ident: ref_103
  article-title: Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects
  publication-title: Drug Metab. Pharmacokinet.
  doi: 10.1016/j.dmpk.2015.01.002
– volume: 35
  start-page: 169
  year: 2010
  ident: ref_13
  article-title: Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS
  publication-title: J. Clin. Pharm. Ther.
  doi: 10.1111/j.1365-2710.2009.01159.x
– volume: 67
  start-page: 535
  year: 2009
  ident: ref_88
  article-title: Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor vera-pamil
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.2009.03396.x
– volume: 56
  start-page: 501
  year: 2003
  ident: ref_1
  article-title: Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pul-monary function
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1046/j.1365-2125.2003.01902.x
– ident: ref_32
  doi: 10.1002/9780470712184
– volume: 11
  start-page: 447
  year: 2020
  ident: ref_12
  article-title: Applying Biopharmaceutical Classification System Criteria to Predict the Potential Effect of Cremophor ® RH 40 on Fexofenadine Bioavailability at Higher Doses
  publication-title: Ther. Deliv.
  doi: 10.4155/tde-2020-0042
– volume: 11
  start-page: 1699
  year: 2022
  ident: ref_17
  article-title: Formulation and evaluation of mouth dissolving films of fexofenadine hydrocloride by solvent casting method
  publication-title: World J. Pharm. Res.
– volume: 36
  start-page: 329
  year: 1999
  ident: ref_14
  article-title: Clinical pharmacology of new histamine H1 receptor antagonists
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/00003088-199936050-00003
– volume: 53
  start-page: 220
  year: 2018
  ident: ref_27
  article-title: ISMP Adverse Drug Reactions: Propofol-Related Infusion Syndrome (PRIS) 1, 2; Ivermectin-Induced Ste-vens-Johnson Syndrome; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Fexofenadine; Memantine-Related Drug Eruption
  publication-title: Hosp. Pharm.
  doi: 10.1177/0018578718776857
– volume: 67
  start-page: 461
  year: 2008
  ident: ref_48
  article-title: LC–MS–MS Assay for Simultaneous Quantification of Fexofenadine and Pseudoephedrine in Human Plasma
  publication-title: Chromatographia
  doi: 10.1365/s10337-008-0526-5
– volume: 51
  start-page: 237
  year: 2012
  ident: ref_95
  article-title: Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/11597070-000000000-00000
– volume: 28
  start-page: 1048
  year: 2014
  ident: ref_53
  article-title: Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: Application to a bioequivalence study
  publication-title: Biomed. Chromatogr.
  doi: 10.1002/bmc.3114
– volume: 6
  start-page: 158
  year: 2014
  ident: ref_100
  article-title: Resveratrol enhances the bioavailability of fexofenadine in healthy human male volunteers: Involvement of P-glycoprotein inhibition
  publication-title: J. Bioequiv Avail.
– volume: 23
  start-page: 514
  year: 2007
  ident: ref_47
  article-title: Rapid and Sensitive LC-MS/MS Method for Quantification of Fexofenadine in Human Plas-ma—Application to a Bioequivalence Study in Chinese Volunteers
  publication-title: Chem. Res. Chin. Univ.
  doi: 10.1016/S1005-9040(07)60112-3
– volume: 24
  start-page: 591
  year: 2008
  ident: ref_82
  article-title: Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharma-cokinetics in healthy subjects
  publication-title: Curr. Med. Res. Opin.
  doi: 10.1185/030079908X260871
– volume: 52
  start-page: 932
  year: 2012
  ident: ref_92
  article-title: Influence of Panax ginseng on Cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) Activity in Healthy Participants
  publication-title: J. Clin. Pharmacol.
  doi: 10.1177/0091270011407194
SSID ssj0000331839
Score 2.34191
SecondaryResourceType review_article
Snippet Background/Objectives: Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically...
Fexofenadine hydrochloride is a widely prescribed drug for treating histamine-mediated allergic reactions. This review systematically collates existing...
SourceID doaj
unpaywall
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1619
SubjectTerms Chronic kidney failure
clearance
Collaboration
Content analysis
Drug dosages
Drugs
fexofenadine
Glycoproteins
Histamine
humans
Internet/Web search services
Medical research
Medicine, Experimental
Metronidazole
Permeability
Pharmacokinetics
Plasma
Prescribing
Search engines
Search strategies
second generation
Stereoisomers
Systematic review
Urticaria
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yL_oinp_1Tokg58vVbZo0bXwQ1uOWQ1AOXOHeQj4RXLrL7S66_70zTa_bQ0EffGwybZOZJPObdvILIa8Li8RSTOTRMp-LOsTcSFXnnhWmUkb6sjsM5tNnefFVfLyqrkZHfWFOWKIHToqbSMOdaVwUtXGicrWylVVROeujCjJ0qy-4sVEw1a3BHMeqSlt2OMT1k9W3_SfiNUPeLInsOiNn1HH2_74yj1zT3W27MrsfZrEY-aDZA3K_B490mhp9SO6E9iE5uUzv3J3S-X4z1fqUntDLPS_17hF533OALoby7wAxUZYuI52Fn8sYMAOsDe_olH4ZKJ5p-n_wmMxn5_Ozi7w_PiF3QlabnIFxvJNeRSYdM6YxzjCpGu-KWAkPtYI72fBYe2t9w5soWayUU6YIhSn5E3LQLtvwjNCSSwNhUgA9WtFEqyQL0Rm4klYCwszI2xs16lUiydAQXKDe9R_1npEPqOxBGDmuuwKwvO4tr_9m-Yy8QVNpnImba-hcv6EA2oycVnralBiMAgjKyPEtSZhB7nb1jbF1P4PXmkPoWEM4KFhGXg3VeCdmpbVhuUUZcBc1gFCekadpkAxdQmANUBEePhlGzb8p5_n_UM4RuVcC_EqJN8fkYHO9DS8APm3sy26m_ALSEhva
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZG9wAvaFwXNpCR0HhZaJw4TowEqEOrJiSqCoq0t8hXkKiS0oug_55zcmsnEOIxtpPYx-fY3_HlO4S8iDQSSzEees1syDPnQyVkFloWqVQqYeM6GMzHibj6wj9cp9cHZNLdhcFjld2YWA_UtjK4Rj5MAMpnAM85e7f4EWLUKNxd7UJoqDa0gn1TU4zdIocxRlUekMOLy8n0U7_qEiWow7K5ypOAvz9cfNstHa8Y8mkJZN3Zm6RqLv8_R-y9Kev2plyo7U81n-_NTeMjcrcFlXTUaME9cuDK--Rs2vxze05nu0tWq3N6Rqc7vurtA_K25Qad9-nfAXpiWVp5Ona_Ku_wZFjpXtMR_dxTP9NmX-EhmY0vZ--vwjasQmi4SNchg06zRljpmTBMqVwZxYTMrYl8yi3k8sSIPPGZ1drmSe4F86k0UkUuUnHyiAzKqnTHhMaJUOA-OZCj5rnXUjDnjYInoQUgz4C86sRYLBryjAKcDpR78Ve5B-QChd0XRu7rOqFafi1aUyqESozKjeeZMjw1mdSpll4abb10wsUBeYldVaCFrpfQuPaiAdQZua6KUR6jkwrgKCCnN0qCZZmb2V1nF61lr4qdHgbkeZ-Nb-JptdJVGywD00gG4DQJyONGSfomIeAGCAkfH_Za83_CefLv6pyQOzEAruaozSkZrJcb9xQA01o_a63gN1lSF-I
  priority: 102
  providerName: ProQuest
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELege4AXxucIDGQkNF6WJo4dJ-YBVBDVhMRUiU4aT5E_Aa1KqjYdlL-ec5KmHfAA4iVS7HOU853tO_vuZ4Sex8oDSxEWOkVMyDLrQslFFhoSy1RIbpLmMpgPp_zkjL0_T893svh9WCW44l-bSbpJkfcIYhHhEUngSUQ0N-71ZbeXRDLKsuamgutoj_sjpgHaOzudjD41h8ld6zZxh4J3H82_bDeKl8SjZ3GPsbOzJDXI_b_PzzsL1I1VOZfrb3I221mJxvtIbnhoA1AuhqtaDfWPX-Ad_4fJ2-hWZ6biUatXd9A1W95FR5OWr_Uxnm7TtpbH-AhPtgjY63voVYc2OuvLL8CY9bS4cnhsv1fO-liz0r7EI_yxB5PG7UnFfTQdv5u-PQm7ixpCzXhahwTUwGhuhCNcEylzqSXhIjc6dikzUMuo5jl1mVHK5DR3nLhUaCFjG8uEPkCDsirtQ4QTyiU4ZBZkpVjulODEOi3hjSsOHRWg4UZUxbyF4yjAjfGyLf4o2wC98QLtiT2adlNQLT4X3eAsuKRa5tqxTGqW6kyoVAkntDJOWG6TAL3w6lD4MV8vgLkudQH-2aNnFaM88W4vmFsBOrxCCWNVX63eKFTRzRXLgoKTmoHjyUiAnvXVvqWPfytttfI0sDBlYO7SAB20itiz5E14MErh41GvmX_XOY_-ucVjdDMBq66N5zlEg3qxsk_AKqvV027g_QTPMjPX
  priority: 102
  providerName: Unpaywall
Title Clinical Pharmacokinetics of Fexofenadine: A Systematic Review
URI https://www.ncbi.nlm.nih.gov/pubmed/39771597
https://www.proquest.com/docview/3149749941
https://www.proquest.com/docview/3153871543
https://www.mdpi.com/1999-4923/16/12/1619/pdf?version=1734701031
https://doaj.org/article/6a3ca8cf47ac45c79b5b9f9cbdf9e6e2
UnpaywallVersion publishedVersion
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: HH5
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://abc-chemistry.org/
  providerName: ABC ChemistRy
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: KQ8
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: ABDBF
  dateStart: 20100901
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: DIK
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: M~E
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: RPM
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1999-4923
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1999-4923
  dateEnd: 20250831
  omitProxy: true
  ssIdentifier: ssj0000331839
  issn: 1999-4923
  databaseCode: M48
  dateStart: 20091001
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLbG9gAviDuBUQUJlZdli2PHiZEAdWjVhLSqglYaT5GvIFGlXS9i_feck6TpKoa0x9iOEx8f-5zPl-8Q8i7WSCxFeeQ1tRHPnI-UkFlkaaxSqYRNqmAwFwNxPuZfL9PLPbI5NtYIcHErtMN4UuP55Pj6av0ZBvxHRJwA2U9mv7arvwuKlFiACrqzqwhjS-EebBNo4x45AHuVoO5fNCCgmq8Z6rWstp8lhlxLWH3V5_-V7xixiuv_3xn9hkm7vypnav1HTSY3bFf_EXnYOJ1hr9aSx2TPlU9Id1h_c30UjraXsBZHYTccbvms10_Jp4Y7dNKm_wbXFMuGUx_23fXUOzw5VroPYS_83lJDh_W-wzMy6p-NvpxHTdiFyHCRLiMKnWqNsNJTYahSuTKKCplbE_uUW8jlzIic-cxqbXOWe0F9Ko1UsYtVwp6T_XJaupckTJhQAK8cyFHz3GspqPNGwZPQAmQdkOONGItZTa5RAChBuRe3yj0gpyjstjByY1cJ0_nPohlqhVDMqNx4ninDU5NJnWrppdHWSydcEpD32FUF6tRyDo1rLiLAPyMXVtHLEwSx4DwF5HCnJIw8s5u96exio7gFA8iZAYzkNCBv22x8E0-zlW66wjJgZjJwXllAXtRK0jYJHXJwMaHyk1Zr7iacV3f43mvyIAGvrD6Pc0j2l_OVewNe1VJ3yMHp2WD4rVOtSnSqIQJp48Gw9-MvCgonYw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLam7WG8IO4EBhgJxstC4zhxYqSBOljVsa2qoEh7s3wFiSopvWj0x_HfOE7StBMI8bLH2E5iH_v4fL6c7yD0IlKeWIokoVPEhElmXSgZz0JDIplyyUxcBYM5H7D-l-TjRXqxhX6tfGH8tcrVnFhN1KbUfo-8QwHKZwDPE_Ju8iP0UaP86eoqhIZsQiuYw4pirHHsOLXLS1jCzQ5PPkB_v4zj3vHofT9sogyEOmHpPCTQBqOZ4Y4wTaTMpZaE8dzoyKWJgdyEapZTlxmlTE5zx4hLueYyspH0vAdgAXYAdVBQqp2j48HwU7vJE1GvMrz2HKKUR53Jt_VO9Yx4-i7mSX42bGIVOuBPA7FhIXcXxUQuL-V4vGEKe7fQzQbD4m496G6jLVvcQfvD-p_LAzxa-3TNDvA-Hq7psZd30duGinTcpn8HpOvL4tLhnv1ZOusvohX2De7izy3TNK6PMe6h0XXI9z7aLsrCPkQ4pkzCas2CHFWSO8UZsU5LeGKKAdAN0OuVGMWk5uoQsMbxchd_lXuAjryw28KeartKKKdfRaO5gkmqZa5dkkmdpDrjKlXcca2M45bZOECvfFcJPyHMp9C4xq8B6uyptUQ3j_2aGLBYgPaulARF1lezV50tmolkJtbDPkDP22z_pr8cV9hy4cuA1coAC9MAPagHSdskj-8BscLHO-2o-T_hPPp3dZ6h3f7o_EycnQxOH6MbMWC9-pbPHtqeTxf2CWC1uXraaARG4pp18DfkWlcb
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgJeEHcCA4wE42WhuTox0kAdW7UxqCropL1ZvoJElZReNPoT-Veck6RpJxDiZY-JncQ-9vH57JzzHUJeBAqJpcLEdyo0fpJZ50vGM9-EgUy5ZCaqksF8GrDjs-TDeXq-RX6tYmHQrXK1JlYLtSk1npF3Y4DyGcDzJOy6xi1ieNh_N_nhYwYp_NO6SqchmzQLZr-iG2uCPE7t8gK2c7P9k0MY-5dR1D8avT_2m4wDvk5YOvdD6I_RzHAXMh1KmUstQ8ZzowOXJgZKk1izPHaZUcrkce5Y6FKuuQxsIJEDAazBdobhoh2yfXA0GH5uD3yCGNWH11FEccyD7uTb-tR6FiKVF0PCnw37WKUR-NNYbFjL64tiIpcXcjzeMIv9W-Rmg2dpr56At8mWLe6Q3WH9zeUeHa3ju2Z7dJcO11TZy7vkbUNLOm7vfwfUi3Vp6Wjf_iydRae0wr6hPfqlZZ2m9S-Ne2R0FfK9TzpFWdiHhEYxk7BzsyBHleROcRZapyVcMcUA9Hrk9UqMYlLzdgjY76DcxV_l7pEDFHZbGWm3qxvl9KtotFgwGWuZa5dkUiepzrhKFXdcK-O4ZTbyyCscKoGLw3wKnWtiHKDNSLMlenmE-2PAZR7ZuVQTlFpfLl4NtmgWlZlYq4BHnrfF-CQ6yhW2XGAdsGAZ4OLYIw_qSdJ2CbE-oFd4ebedNf8nnEf_bs4zcg10UXw8GZw-JjcigH21w88O6cynC_sEYNtcPW0UghJxxSr4G5-wW1U
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELege4AXxucIDGQkNF6WJo4dJ-YBVBDVhMRUiU4aT5E_Aa1KqjYdlL-ec5KmHfAA4iVS7HOU853tO_vuZ4Sex8oDSxEWOkVMyDLrQslFFhoSy1RIbpLmMpgPp_zkjL0_T893svh9WCW44l-bSbpJkfcIYhHhEUngSUQ0N-71ZbeXRDLKsuamgutoj_sjpgHaOzudjD41h8ld6zZxh4J3H82_bDeKl8SjZ3GPsbOzJDXI_b_PzzsL1I1VOZfrb3I221mJxvtIbnhoA1AuhqtaDfWPX-Ad_4fJ2-hWZ6biUatXd9A1W95FR5OWr_Uxnm7TtpbH-AhPtgjY63voVYc2OuvLL8CY9bS4cnhsv1fO-liz0r7EI_yxB5PG7UnFfTQdv5u-PQm7ixpCzXhahwTUwGhuhCNcEylzqSXhIjc6dikzUMuo5jl1mVHK5DR3nLhUaCFjG8uEPkCDsirtQ4QTyiU4ZBZkpVjulODEOi3hjSsOHRWg4UZUxbyF4yjAjfGyLf4o2wC98QLtiT2adlNQLT4X3eAsuKRa5tqxTGqW6kyoVAkntDJOWG6TAL3w6lD4MV8vgLkudQH-2aNnFaM88W4vmFsBOrxCCWNVX63eKFTRzRXLgoKTmoHjyUiAnvXVvqWPfytttfI0sDBlYO7SAB20itiz5E14MErh41GvmX_XOY_-ucVjdDMBq66N5zlEg3qxsk_AKqvV027g_QTPMjPX
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Pharmacokinetics+of+Fexofenadine%3A+A+Systematic+Review&rft.jtitle=Pharmaceutics&rft.au=Batool%2C+Maryam&rft.au=Zamir%2C+Ammara&rft.au=Alqahtani%2C+Faleh&rft.au=Ahmad%2C+Tanveer&rft.date=2024-12-01&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=16&rft.issue=12&rft_id=info:doi/10.3390%2Fpharmaceutics16121619&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon